A Bird's Eye View of the Potential Role of NFKBIA in Pan-cancer

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 May 30

PMID 38813139

Authors

Bin Wang

Difang Sun

Haifeng Li

Jinli Chen

Affiliations

Soon will be listed here.

Abstract

In the 21st century, cancer remains a serious threat to people's health and has become a prominent public health problem. NFKBIA is involved in the pathological process of many diseases including cancer, but its specific role in pan-cancer has not yet been fully elucidated. This study aims to deepen the understanding of cancer pathology by analyzing the potential functions of NFKBIA in pan-cancer. We used TCGA data to analyze differences of expression of NFKBIA in pan-cancer. We explored the prognostic value, clinical relevance, immune relevance, potential biological function, and diagnosis and treatment value of NFKBIA in pan-cancer through bioinformatics analysis. This study found that in pan-cancer, NFKBIA exhibits differences in expression, which correlate with the prognosis, diagnosis, treatment value and clinical and immune parameters. We have identified that Aspirin, Astaxanthin and Bardoxolone methyl are expected to play a potential therapeutic role in pan-cancer. The results of this study will help to improve our understanding of the role and potential mechanism of NFKBIA in cancer pathology, which may provide guidance for cancer-related research and clinical diagnosis and treatment.

Citing Articles

Integrative approach to decipher pharmacological mechanism of Cinnamomum zeylanicum essential oil in prostate cancer.

Mohanty D, Padhee S, Priyadarshini A, Kerry R, Dash B, Sahoo A Med Oncol. 2025; 42(4):100.

PMID: 40072751 DOI: 10.1007/s12032-025-02665-w.

References

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388(10053):1545-1602. PMC: 5055577. DOI: 10.1016/S0140-6736(16)31678-6. View

Schmid J, Birbach A . IkappaB kinase beta (IKKbeta/IKK2/IKBKB)--a key molecule in signaling to the transcription factor NF-kappaB. Cytokine Growth Factor Rev. 2008; 19(2):157-65. DOI: 10.1016/j.cytogfr.2008.01.006. View

Chang W, Lai A . Aberrations in Notch-Hedgehog signalling reveal cancer stem cells harbouring conserved oncogenic properties associated with hypoxia and immunoevasion. Br J Cancer. 2019; 121(8):666-678. PMC: 6889439. DOI: 10.1038/s41416-019-0572-9. View

Wu H, Niu H, Shao A, Wu C, Dixon B, Zhang J . Astaxanthin as a Potential Neuroprotective Agent for Neurological Diseases. Mar Drugs. 2015; 13(9):5750-66. PMC: 4584352. DOI: 10.3390/md13095750. View

Ozben T . Antioxidant Supplementation on Cancer Risk and Concurrent Use of Antioxidants during Cancer Therapy: An Update. Curr Top Med Chem. 2014; . View

Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A . The reactome pathway knowledgebase. Nucleic Acids Res. 2019; 48(D1):D498-D503. PMC: 7145712. DOI: 10.1093/nar/gkz1031. View

Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J . pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011; 12:77. PMC: 3068975. DOI: 10.1186/1471-2105-12-77. View

Szklarczyk D, Gable A, Lyon D, Junge A, Wyder S, Huerta-Cepas J . STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2018; 47(D1):D607-D613. PMC: 6323986. DOI: 10.1093/nar/gky1131. View

10.

Nath N, Vassell R, Chattopadhyay M, Kogan M, Kashfi K . Nitro-aspirin inhibits MCF-7 breast cancer cell growth: effects on COX-2 expression and Wnt/beta-catenin/TCF-4 signaling. Biochem Pharmacol. 2009; 78(10):1298-304. DOI: 10.1016/j.bcp.2009.06.104. View

11.

Wishart D, Feunang Y, Guo A, Lo E, Marcu A, Grant J . DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2017; 46(D1):D1074-D1082. PMC: 5753335. DOI: 10.1093/nar/gkx1037. View

12.

Batista A, Rodvold J, Xian S, Searles S, Lew A, Iwawaki T . IRE1α regulates macrophage polarization, PD-L1 expression, and tumor survival. PLoS Biol. 2020; 18(6):e3000687. PMC: 7307794. DOI: 10.1371/journal.pbio.3000687. View

13.

Solinas C, Martinez Chanza N, Awada A, Scartozzi M . The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges. Cancer Treat Rev. 2017; 53:138-145. DOI: 10.1016/j.ctrv.2016.12.004. View

14.

Tate J, Bamford S, Jubb H, Sondka Z, Beare D, Bindal N . COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2018; 47(D1):D941-D947. PMC: 6323903. DOI: 10.1093/nar/gky1015. View

15.

McNamara M, Jacobs T, Lamarca A, Hubner R, Valle J, Amir E . Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. Cancer Treat Rev. 2020; 89:102084. DOI: 10.1016/j.ctrv.2020.102084. View

16.

Zhou L, Wang Z, Yu S, Xiong Y, Fan J, Lyu Y . CDDO-Me Elicits Anti-Breast Cancer Activity by Targeting LRP6 and FZD7 Receptor Complex. J Pharmacol Exp Ther. 2020; 373(1):149-159. DOI: 10.1124/jpet.119.263434. View

17.

Wu H, Wang Z, Zhao Q, Chen D, He M, Yang L . Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers. Ann Transl Med. 2020; 7(22):640. PMC: 6944566. DOI: 10.21037/atm.2019.10.116. View

18.

Ponten F, Jirstrom K, Uhlen M . The Human Protein Atlas--a tool for pathology. J Pathol. 2008; 216(4):387-93. DOI: 10.1002/path.2440. View

19.

Wang Y, Zhe H, Zhao R . Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment. Mol Cancer. 2014; 13:30. PMC: 3940295. DOI: 10.1186/1476-4598-13-30. View

20.

Elia G, Ferrari S, Galdiero M, Ragusa F, Paparo S, Ruffilli I . New insight in endocrine-related adverse events associated to immune checkpoint blockade. Best Pract Res Clin Endocrinol Metab. 2020; 34(1):101370. DOI: 10.1016/j.beem.2019.101370. View